1. 124I-MIBG: a new promising positron-emitting radiopharmaceutical for the evaluation of neuroblastoma
- Author
-
Umberto Ficola, Pietro Coppolino, Arnoldo Piccardo, Angelina Cistaro, Rosario Paratore, Natale Quartuccio, Alessandro Sperandeo, Federico Caobelli, and Gaspare Arnone
- Subjects
Male ,medicine.medical_specialty ,Electrons ,Computed tomography ,3-Iodobenzylguanidine ,Scintigraphy ,Multimodal Imaging ,Neuroblastoma ,Positron ,medicine ,Humans ,Radiology, Nuclear Medicine and imaging ,Child ,Solid tumor ,medicine.diagnostic_test ,business.industry ,General Medicine ,medicine.disease ,Positron emission tomography ,Positron-Emission Tomography ,Female ,Radiology ,Tomography ,Radiopharmaceuticals ,Tomography, X-Ray Computed ,Nuclear medicine ,business - Abstract
Neuroblastoma is the most common extra-cranial solid tumor in pediatric patients. Despite the established role of 123I-MIBG and 131I-MIBG scintigraphy in this tumor, only limited data are available regarding the use of 124I-metaiodobenzylguanidine (MIBG) positron emission tomography (PET)/computed tomography (CT). We present our preliminary experience with 124I-MIBG PET/CT: two pediatric patients affected by neuroblastoma, who underwent 124I-MIBG PET/CT for pre-therapy distribution evaluation and restaging purposes. We aimed to evaluate whether 124I-MIBG PET/CT can detect as many or more neuroblastoma lesions than 123I/131I-MIBG imaging. Our cases show promising results, although further validation and standardization of 124I-MIBG PET/CT are required.
- Published
- 2015
- Full Text
- View/download PDF